2026-05-22T00:53:55Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/184482024-11-28T14:42:40Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16982
Repisalud author Carmona-Hidalgo, Beatriz author García-Martín, Adela author Muñoz, Eduardo author González-Mariscal, Isabel authoraffiliation [Carmona-Hidalgo,B; Carmona-Hidalgo,B] Emerald Health Biotechnology, Córdoba, Spain. [Muñoz,E] Instituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Hospital Universitario Reina Sofía, Córdoba, Spain. [González-Mariscal,I] Instituto de Investigación Biomédica de Málaga-IBIMA, UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Málaga, Spain. 2024-02-19T15:30:48Z 2024-02-19T15:30:48Z 2021-08-28 10.3390/ph14090863 1999-4923 Pharmaceuticals http://hdl.handle.net/10668/4264 34577563 http://hdl.handle.net/20.500.12105/18448 Anti-inflammatory and antidiabetogenic properties have been ascribed to cannabidiol (CBD). CBD-based medicinal drugs have been approved for over a lustrum, and a boom in the commercialization of CBD products started in parallel. Herein, we explored the efficacy of CBD in streptozotocin (STZ)-induced diabetic mice to prevent diabetic nephropathy at onset. Eight-to-ten-week-old C57BL6J male mice were treated daily intraperitoneally with 10 mg/kg of CBD or vehicle for 14 days. After 8 days of treatment, mice were challenged with STZ or vehicle (healthy-control). At the end of the study, non-fasting blood glucose (FBG) level was 276 ± 42 mg/dL in vehicle-STZ-treated compared to 147 ± 9 mg/dL (p ≤ 0.01) in healthy-control mice. FBG was 114 ± 8 mg/dL in vehicle-STZ-treated compared to 89 ± 4 mg/dL in healthy-control mice (p ≤ 0.05). CBD treatment did not prevent STZ-induced hyperglycemia, and non-FBG and FBG levels were 341 ± 40 and 133 ± 26 mg/dL, respectively. Additionally, treatment with CBD did not avert STZ-induced glucose intolerance or pancreatic beta cell mass loss compared to vehicle-STZ-treated mice. Anatomopathological examination showed that kidneys from vehicle-STZ-treated mice had a 35% increase of glomerular size compared to healthy-control mice (p ≤ 0.001) and presented lesions with a 43% increase in fibrosis and T cell infiltration (p ≤ 0.001). Although treatment with CBD prevented glomerular hypertrophy and reduced T cell infiltration, it significantly worsened overall renal damage (p ≤ 0.05 compared to vehicle-STZ mice), leading to a more severe renal dysfunction than STZ alone. In conclusion, we showed that CBD could be detrimental for patients with type 1 diabetes, particularly those undergoing complications such as diabetic nephropathy. eng Cannabinoid Streptozotocin Phytocannabinoid Type 1 diabetes Endocannabinoid system Chronic kidney disease Cannabinoides Diabetes Mellitus experimental Diabetes Mellitus tipo 1 Endocannabinoides Insuficiencia renal crónica Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice research article